Sanofi, Regeneron Shares Pop On Big News About COPD Treatment

Tuesday, 28 March 2023, 23:29:49
Shares of Sanofi were up 10.20% the week ended March 24, while Regeneron finished with a gain of 9.68%, following promising news about the company’s jointly developed medication Dupixent. Clinical trial results showed the drug reduced severe flare-ups of COPD at a far better rate than a placebo. There are currently no equivalent treatments for […]
— ValueWalk

Amgen-Sanofi patent case divides makers of antibody drugs

Tuesday, 28 March 2023, 00:51:41
Amgen Inc’s battle with Sanofi and Regeneron at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition among companies that make antibody medicines. In the dispute with Sanofi and partner Regeneron, whose cholesterol-lowering monoclonal antibody drug Praluent works in a […]
— Financial Post

Supreme Court hears arguments in Amgen Repatha patent case against Sanofi

Monday, 27 March 2023, 19:45:10
The U.S. Supreme Court earlier Monday heard arguments in a patent case filed by Amgen regarding Repatha against Sanofi. Read more here.
— Seeking Alpha

Argus maintains Sanofi ADR at Buy

Monday, 27 March 2023, 16:54:37
https://www.investing.com/news/pro/sanofi-receives-investment-bank-analyst-rating-update-3041221
— Investing.com

U.S. Supreme Court hears Amgen bid to revive cholesterol drug patents

Monday, 27 March 2023, 16:35:50
WASHINGTON — The U.S. Supreme Court on Monday began hearing a bid by Amgen Inc to revive patents on its cholesterol-lowering drug Repatha in a legal effort that rival Sanofi SA called a “blatant attempt” to squeeze competitors out of the market. Amgen is appealing a lower court’s ruling that invalidated two of its patents […]
— Financial Post